Who are Visipaque 270's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Imeron, E-Z-Hd, Ultravist 370, Ioxitol, Optiray 320, Omnipaque 180.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iodixanol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Visipaque 270 — Competitive Intelligence Brief

Visipaque 270 (IODIXANOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiographic Contrast Agent. Area: Hematology.

marketed Radiographic Contrast Agent Hematology Live · refreshed every 30 min

Target snapshot

Visipaque 270 (IODIXANOL) — GE HealthCare. Visipaque 270 works by increasing the density of fluids in the body, making them visible on X-ray images.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
Visipaque 270 TARGET	IODIXANOL	GE HealthCare	marketed	Radiographic Contrast Agent	1996-01-01
Imeron	IOMEPROL		marketed	Radiographic Contrast Agent [EPC]	2024-01-01
E-Z-Hd	BARIUM SULFATE		marketed	Radiographic Contrast Agent [EPC]	2016-01-01
Ultravist 370	IOPROMIDE	Bayer	marketed	Radiographic Contrast Agent	1995-01-01
Ioxitol	IOXILAN	Guerbet	marketed	Radiographic Contrast Agent	1995-01-01
Optiray 320	IOVERSOL	Liebel-Flarsheim	marketed	Radiographic Contrast Agent [EPC]	1988-01-01
Omnipaque 180	IOHEXOL	GE HealthCare	marketed	Radiographic Contrast Agent [EPC]	1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiographic Contrast Agent class)

Bracco · 2 drugs in this class
GE HealthCare · 2 drugs in this class
Bayer · 1 drug in this class
Guerbet · 1 drug in this class
University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Visipaque 270 — Competitive Intelligence Brief. https://druglandscape.com/ci/iodixanol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab